



PTO/SB/08a(08/03)  
Approved for use through 07/31/2006. OMB 0651-0031  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<b>Application Number</b>	<b>10/642,440</b>		
	<b>Filing Date</b>	<b>August 14, 2003</b>		
	<b>First Named Inventor</b>	<b>Eli Wallace</b>		
	<b>Art Unit</b>	<del>4014</del> <b>1624</b>		
	<b>Examiner Name</b>			
<b>Sheet</b>	<b>1</b>	<b>of</b>	<b>Attorney Docket No.</b>	<b>ARR002</b>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published	T <sup>2</sup>
TNT ✓	1	DAVID W. RUSNAK, et al., The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines <i>in Vitro</i> and <i>in Vivo</i> , <i>Molecular Cancer Therapeutics</i> , 2001, Vol. 1 (December) pp. 85-94 ,	
TNT ✓	2	DAVID W. RUSNAK, et al., The Characterization of Novel, Dual ErbB-2/EGFR, Tyrosine Kinase Inhibitors: Potential Therapy for Cancer, <i>Cancer Research</i> , Vol. 61, pp. 7196-7203, October 1, 2001 ,	

<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b>	<b>3/1<sup>st</sup>/06</b>
-------------------------------	--	----------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

